194 related articles for article (PubMed ID: 15990899)
1. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors.
Laakso M; Loman N; Borg A; Isola J
Mod Pathol; 2005 Oct; 18(10):1321-8. PubMed ID: 15990899
[TBL] [Abstract][Full Text] [Related]
2. p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
Ribeiro-Silva A; Ramalho LN; Garcia SB; Brandão DF; Chahud F; Zucoloto S
Histopathology; 2005 Nov; 47(5):458-66. PubMed ID: 16241993
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM
Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
[TBL] [Abstract][Full Text] [Related]
4. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
5. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
7. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT
Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143
[TBL] [Abstract][Full Text] [Related]
8. Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients.
Stefansson IM; Salvesen HB; Akslen LA
Int J Cancer; 2006 Mar; 118(5):1227-33. PubMed ID: 16152605
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
10. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome.
Azoulay S; Laé M; Fréneaux P; Merle S; Al Ghuzlan A; Chnecker C; Rosty C; Klijanienko J; Sigal-Zafrani B; Salmon R; Fourquet A; Sastre-Garau X; Vincent-Salomon A
Mod Pathol; 2005 Dec; 18(12):1623-31. PubMed ID: 16258515
[TBL] [Abstract][Full Text] [Related]
11. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
12. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
13. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
Matos I; Dufloth R; Alvarenga M; Zeferino LC; Schmitt F
Virchows Arch; 2005 Oct; 447(4):688-94. PubMed ID: 16012853
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Hardisson D; Calero F; Benitez J; Palacios J
Clin Cancer Res; 2006 Mar; 12(5):1533-9. PubMed ID: 16533778
[TBL] [Abstract][Full Text] [Related]
15. Centrally necrotizing carcinoma of the breast: clinicopathological analysis of 33 cases indicating its basal-like phenotype and poor prognosis.
Yu L; Yang W; Cai X; Shi D; Fan Y; Lu H
Histopathology; 2010 Aug; 57(2):193-201. PubMed ID: 20716161
[TBL] [Abstract][Full Text] [Related]
16. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Jumppanen M; Gruvberger-Saal S; Kauraniemi P; Tanner M; Bendahl PO; Lundin M; Krogh M; Kataja P; Borg A; Fernö M; Isola J
Breast Cancer Res; 2007; 9(1):R16. PubMed ID: 17263897
[TBL] [Abstract][Full Text] [Related]
17. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast--a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells.
Hungermann D; Buerger H; Oehlschlegel C; Herbst H; Boecker W
BMC Cancer; 2005 Jul; 5():92. PubMed ID: 16050957
[TBL] [Abstract][Full Text] [Related]
18. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
19. BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.
Mohanty SK; Lai JP; Gordon OK; Pradhan D; Bose S; Dadmanesh F
Breast J; 2015; 21(6):596-603. PubMed ID: 26390986
[TBL] [Abstract][Full Text] [Related]
20. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup.
Shekhar MP; Kato I; Nangia-Makker P; Tait L
Oncotarget; 2013 Feb; 4(2):231-41. PubMed ID: 23548208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
